Does tadalafil affect vision? Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor licensed in the UK for erectile dysfunction and benign prostatic hyperplasia, can occasionally cause visual side effects, though serious disturbances remain uncommon. The mechanism relates to mild cross-reactivity with PDE6 enzymes in retinal photoreceptors. Whilst most visual effects are transient and resolve as the medication is metabolised, understanding the difference between benign symptoms and rare serious complications is essential. The MHRA recognises visual side effects as part of tadalafil's known safety profile, and patients should report concerning symptoms to their healthcare professional.

Does Tadalafil Affect Vision?

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor licensed in the UK for treating erectile dysfunction and benign prostatic hyperplasia. Whilst generally well-tolerated, tadalafil can occasionally affect vision, though serious visual disturbances remain uncommon. The Medicines and Healthcare products Regulatory Agency (MHRA) recognises visual side effects as part of the known safety profile for this class of medication.

The mechanism underlying visual effects relates to tadalafil's pharmacological action. Although highly selective for PDE5 enzymes found predominantly in vascular smooth muscle, tadalafil exhibits mild cross-reactivity with PDE6 enzymes present in retinal photoreceptors. This interaction can temporarily alter visual processing.

Possible (generally uncommon) visual effects include:

• Blurred vision

• Changes in colour perception (rare with tadalafil)

• Visual disturbances

These effects are typically transient and resolve spontaneously as the medication is metabolised. The half-life of tadalafil is about 17.5 hours, meaning visual symptoms usually diminish as the drug is eliminated from the body. Most patients who experience these minor visual changes can continue treatment safely under medical supervision. However, understanding the distinction between uncommon, benign effects and rare but serious complications is essential for patient safety and informed decision-making regarding continued therapy.

If you experience any concerning visual symptoms while taking tadalafil, you should report them to your healthcare professional and consider reporting via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Recognising Serious Vision Side Effects

Whilst mild visual disturbances are relatively uncommon with tadalafil, certain serious ocular events require immediate medical attention. The most concerning complication is non-arteritic anterior ischaemic optic neuropathy (NAION), a rare condition causing sudden, painless vision loss due to reduced blood flow to the optic nerve. Although epidemiological studies have not definitively established causation, the MHRA advises that patients experiencing sudden vision loss should discontinue tadalafil immediately and seek urgent ophthalmological assessment.

Warning signs of serious vision problems include:

• Sudden loss of vision in one or both eyes

• Sudden decrease in visual acuity that does not improve

• Persistent visual field defects (blind spots)

• Prolonged visual disturbances persisting beyond 24-36 hours after taking tadalafil

There have been isolated case reports of other eye conditions in patients taking PDE5 inhibitors, though a causal relationship has not been established. These include reports of central serous chorioretinopathy (fluid accumulation beneath the retina) and retinal vascular occlusions.

The Summary of Product Characteristics (SmPC) for tadalafil emphasises that patients with a history of NAION in either eye should not use this medication, as the risk of recurrence may be elevated. Healthcare professionals should conduct a thorough ophthalmic history before prescribing tadalafil, particularly in patients with pre-existing retinal disorders or significant cardiovascular disease, as these factors may compound risk.

Who Is at Higher Risk of Vision Problems?

Certain patient populations face elevated risk of experiencing vision-related adverse effects with tadalafil therapy. Understanding these risk factors enables clinicians to make informed prescribing decisions and counsel patients appropriately about potential complications.

High-risk groups include:

Patients with pre-existing eye conditions: The tadalafil SmPC advises that use is not recommended in patients with hereditary degenerative retinal disorders, including retinitis pigmentosa, due to limited data. For patients with diabetic retinopathy, age-related macular degeneration, or glaucoma, clinical judgement on a case-by-case basis is advised, as the effects of tadalafil in these conditions have not been systematically studied.

Cardiovascular disease patients: Those with hypertension, coronary artery disease, or previous stroke may have compromised ocular blood flow, potentially increasing susceptibility to ischaemic optic events. The overlap between erectile dysfunction and cardiovascular disease means many tadalafil users inherently belong to this higher-risk category.

Patients with NAION risk factors: These include age over 50, smoking, diabetes, hypertension, high cholesterol, and certain anatomical features of the optic disc.

Patients taking multiple medications: Concomitant use of alpha-blockers may cause additive blood pressure-lowering effects; patients should be stable on alpha-blocker therapy before starting tadalafil, and the lowest dose should be considered. Nitrates are absolutely contraindicated due to severe hypotension risk. Guanylate cyclase stimulators such as riociguat are also contraindicated. CYP3A4 inhibitors such as ritonavir, ketoconazole, or erythromycin increase tadalafil plasma levels, potentially heightening the risk of adverse effects.

NICE Clinical Knowledge Summary guidance recommends cardiovascular assessment before initiating PDE5 inhibitor therapy to ensure suitability for sexual activity and to assess the underlying causes of erectile dysfunction.

When to Seek Medical Advice About Vision Changes

Patients prescribed tadalafil should receive clear guidance on when visual symptoms warrant medical review. Distinguishing between self-limiting effects and those requiring urgent intervention is crucial for preventing permanent visual impairment.

Seek immediate emergency care (attend A&E, eye casualty or call 999) if you experience:

• Sudden loss of vision in one or both eyes

• Sudden onset of severe eye pain

• Rapid deterioration in visual acuity

• New onset of flashing lights or floaters accompanied by vision loss

These symptoms may indicate NAION, retinal detachment, or vascular occlusion—all ophthalmic emergencies requiring same-day specialist assessment. Patients should be explicitly instructed not to take further doses of tadalafil if sudden vision loss occurs.

Contact your GP, NHS 111, or local urgent eye service within 24 hours if you notice:

• Visual disturbances persisting beyond 24-36 hours after taking tadalafil

• Progressive worsening of colour vision abnormalities

• New blind spots or visual field defects

• Persistent blurred vision affecting daily activities

• Any visual symptoms causing significant concern

For mild, transient visual changes that resolve within hours, patients may continue treatment but should mention these effects at their next routine appointment. The prescriber can then assess whether dose adjustment or alternative therapy is appropriate.

The NHS advises that all patients taking tadalafil should undergo regular medication reviews, typically annually for those on long-term therapy. These reviews provide opportunity to discuss any emerging side effects, reassess cardiovascular risk, and ensure continued appropriateness of treatment. Patients should maintain an up-to-date list of all medications and inform both their GP and any treating ophthalmologist about tadalafil use, as this information is vital for accurate diagnosis should visual problems arise. Pharmacists also play a key role in reinforcing safety messages when dispensing tadalafil, particularly for first-time users.

Remember to report any suspected side effects to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions